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Objective To report clinical characteristics and medical history data obtained retrospectively for a large cohort of
pediatric patients with perinatal and infantile hypophosphatasia.
Study designMedical records from academic medical centers known to diagnose and/or treat hypophosphata-
sia were reviewed. Patients born between 1970 and 2011 with hypophosphatasia and any of the following signs/
symptoms at age <6 months were eligible: vitamin B6–dependent seizures, respiratory compromise, or rachitic
chest deformity (NCT01419028). Patient demographics and characteristics, respiratory support requirements,
invasive ventilator–free survival, and further complications of hypophosphatasia were followed for up to the first
5 years of life.
Results Forty-eight patients represented 12 study sites in 7 countries; 13 patients were alive, and 35 were dead
(including 1 stillborn). Chest deformity, respiratory distress, respiratory failure (as conditioned by the eligibility
criteria), failure to thrive, and elevated calcium levels were present in >70% of patients between birth and age
5 years. Vitamin B6–dependent seizures and respiratory distress and failure were associated significantly
(P < .05) with the risk of early death. Serum alkaline phosphatase activity in all 41 patients tested (mean [SD]:
18.1 [15.4] U/L) was below the mean lower limit of normal of the reference ranges of the various laboratories
(88.2 U/L). Among the 45 patients with relevant data, 29 had received respiratory support, of whom 26 had died
at the time of data collection. The likelihood of invasive ventilator–free survival for this cohort decreased to 63%
at 3 months, 54% at 6 months, 31% at 12 months, and 25% at 5 years.
Conclusions Patients with perinatal or infantile hypophosphatasia and vitamin B6–dependent seizures, with or
without significant respiratory distress or chest deformities, have high morbidity and mortality in the first 5 years
of life. (J Pediatr 2019;209:116-24).
Trial registration ClinicalTrials.gov: NCT01419028.H
ypophosphatasia is the rare inborn-error-of-metabolism characterized enzymatically by low activity of the tissue-
nonspecific isoenzyme of alkaline phosphatase (TNSALP).1-3 In hypophosphatasia, deficient activity of TNSALP on
cell surfaces leads to extracellular accumulation of its natural substrates: inorganic pyrophosphate (PPi), a potent in-
hibitor of hydroxyapatite crystal growth; pyridoxal 50-phosphate (PLP), the major circulating form of vitamin B6; and phos-
phoethanolamine (PEA), a degradation product of cell-surface phosphatidylinositol–glycan anchors for various ectoproteins
like TNSALP.1,2,4 Because PPi inhibits hydroxyapatite crystal propagation, sufficiently high extracellular PPi levels in hypo-From the 1Center for Metabolic Bone Disease and
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phosphatasia can impair mineralization of the growing skeleton, causing rickets,
and can lead to osteomalacia in adults.1,2,5 TNSALP dephosphorylates PLP to
pyridoxal to cross the blood–brain barrier and enter neurons. Thus, profound
TNSALP deficiency in the most severely affected patients with hypophosphatasia
also can compromise neurotransmitter synthesis and cause vitamin B6–depen-
dent seizures.1,6
Largely owing to genetic heterogeneity, hypophosphatasia severity is broad-
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Volume 209  June 2019to arthropathies and/or dental complications without skeletal
abnormalities in adult life.1,2 The clinical nosology of pediatric
hypophosphatasia, aiming to organize this continuum, now
includes (by increasing severity) odonto-hypophosphatasia,
mild childhood hypophosphatasia, severe childhood hypo-
phosphatasia, infantile hypophosphatasia, and perinatal
hypophosphatasia.1,7,8 Benign prenatal hypophosphatasia
also has been described; it is characterized by skeletal
manifestations detected in utero or at birth that improve
spontaneously ex utero, with outcomes ranging from
odonto-hypophosphatasia to infantile hypophosphatasia.9
Information concerning the prevalence and nature of hy-
pophosphatasia complications and survival rates with
supportive care alone is incomplete for perinatal hypophos-
phatasia, which manifests in utero and is apparent at birth,
and infantile hypophosphatasia, which presents before
6 months of age.1,2 Death from these 2 life-threatening forms
of hypophosphatasia seems to result most often from respira-
tory complications caused by poor mineralization of the
bones of the thorax.1,10,11 Perinatal hypophosphatasia is
considered almost always fatal within a few days after birth,
and mortality in infantile hypophosphatasia has been esti-
mated as approximately 50% during the first year of life.1,2
However, no published comprehensive retrospective or pro-
spective studies include a global compilation of the features
of life-threatening perinatal and infantile hypophosphatasia.
Herein we describe the natural history of patients with
perinatal or infantile hypophosphatasia receiving supportive
care born between 1970 and 2011. They were selected for this
study because they displayed the severe manifestations of hy-
pophosphatasia (eg, respiratory compromise, seizures, chest
deformity) of a cohort of patients who began a clinical study
of enzyme replacement therapy in 2008 (asfotase alfa; Stren-
siq, Alexion Pharmaceuticals, Inc, Boston, Massachusetts).12
A portion of the data from that study regarding overall sur-
vival and ventilatory support requirements was published
in 2016,13 and the findings after an average of 7 years of treat-
ment were published in 2019.14 Now we report unpublished
data concerning clinical characteristics including signs,
symptoms, and complications; medical history (including
respiratory support, medications, and hospitalizations);
and routine clinical laboratory values and ALPL mutations
in this natural history cohort of patients with perinatal or in-
fantile hypophosphatasia.Methods
This multinational, noninterventional, retrospective chart
review of the natural history of perinatal and infantile
hypophosphatasia (ClinicalTrials.gov: NCT01419028) was
performed at academic medical centers that had diagnosed
and/ormanaged severe pediatric hypophosphatasia. The study
was conducted in accordance with guidelines set by theWorld
Medical Association Declaration of Helsinki and the Interna-
tional Conference on Harmonisation Guideline for Good
Clinical Practice and in compliance with national, state, andlocal laws of the appropriate regulatory authorities. The study
protocol and subsequent amendments were approved at each
institution by the institutional review board, independent
ethics committee, or research ethics board. Details regarding
patient informed consent are provided in Appendix 2,
Methods (available at www.jpeds.com).Study Design and Patients
Physicians with access to records of patients with hypo-
phosphatasia were identified and contacted via e-mail by
the study sponsor. Examples of recruitment efforts included
outreach to physicians with experience in metabolic bone
diseases and genetic testing laboratories to obtain lists of
physicians who had referred DNA samples that were posi-
tive for ALPL mutation(s). Medical records from patients
(living or dead) were reviewed if the diagnosis of hypophos-
phatasia had included at least 1 of the following: (1) ALPL
mutation(s); (2) serum alkaline phosphatase (ALP) activity
below the normal range and either plasma PLP or urinary
PEA levels above the laboratory’s upper limit of normal
(ULN); or (3) serum ALP activity below the normal range
and report of hypophosphatasia-related radiographic ab-
normalities. In addition, patients were required to have
signs and symptoms characteristic of hypophosphatasia
before 6 months of age and at least 1 of the following hypo-
phosphatasia characteristics associated with significant clin-
ical compromise and poor outcomes: (1) respiratory
complications that required respiratory support measures
or medication(s) and/or that were associated with other
pulmonary problems (eg, pneumonia, respiratory tract
infection, respiratory failure); (2) vitamin B6–dependent
seizures (ie, responsive to supplemental pyridoxine); or
(3) rachitic chest deformity. These represent features of “se-
vere” pediatric hypophosphatasia and therefore would likely
exclude benign prenatal hypophosphatasia9 and less severe
instances of infantile hypophosphatasia. Thus, the medical
records evaluated in our study represented patients with
perinatal or infantile hypophosphatasia likely to show
high morbidity and mortality. Exclusion criteria included
any other clinically significant disease or other treatment
with asfotase alfa at any time before data abstraction.Data Collection
Abstraction of the medical record onto case report forms by
trained personnel occurred at a single time point between
September 2012 and April 2013. Data from up to the patient’s
fifth birthday were collected. This included demographics;
diagnostic history, including age at hypophosphatasia diag-
nosis; clinical laboratory results (serum ALP, urine PEA,
and plasma PLP) obtained closest to the date of diagnosis;
ALPL gene mutation analysis results; and clinical course
including comorbidities, mention of developmental delays,
hospitalizations, medications, therapies, and procedures.
Additional data collected included date, cause, and age of
death. Details regarding data collection are provided in
Appendix 2, Methods.117
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Information regarding the primary outcome measure of
overall survival and the tertiary outcome measure of ventila-
tory support status was published in 2016.13 Secondary and
tertiary assessments, reported herein, include the proportion
of patients requiring invasive ventilation (mechanical via
intubation or tracheostomy) or noninvasive respiratory sup-
port (continuous or bilevel positive airway pressure or sup-
plemental oxygen) stratified by mortality, and by invasive
ventilator–free survival time (IVFST). IVFST is henceforth
defined as time to first invasive ventilation or death. Respira-
tory “distress” and “failure” were defined as transient vs
chronic respiratory difficulty, respectively. Additional assess-
ments included radiographic findings reported at the time of
hypophosphatasia diagnosis, medication history, hospitaliza-
tions, prevalent and clinically important signs, symptoms,
and complications of hypophosphatasia (stratified by mor-
tality) and association with death.
Statistical Analyses
All available data were included in the statistical analyses.
Because data collection was retrospective, not all patients
had complete information. No imputation was performed
for missing data except when only a partial birthdate was pro-
vided (ie, if the day was missing, it was set to 15, and if the
month was missing, it was set to June). Data were censored,
if applicable, at date of data collection for living patients and
at date of last contact for patients whose status was unknown
at data collection. All statistical analyses were conducted using
SAS release 9.2 (SAS Institute, Inc, Cary, North Carolina).
IVFST estimates were quantified using the Kaplan–Meier
method. Survival and invasive respiratory support data (ie,
mechanical via intubation or tracheostomy) were considered
simultaneously and used to calculate the time to first invasive
ventilation or death. CIs were generated using the Greenwood
formula for variance, and CIs for proportions were generated
using the normal approximation to the binomial distribution.
All CIs were 2 sided, with a significance level set at alpha = .05.
Any P values, if generated, were nominal. The association of
the relative risk of death with select hypophosphatasia compli-
cations was also individually and separately examined post hoc
without considering mutual correlation and confounding ef-
fects. Similarly, CIs for relative risks were obtained by
assuming the normal approximation to the binomial distribu-
tion. Percentages of patients were calculated and are provided
below only when the denominator was 48 (representing the
entire enrolled group). All other data are presented as n/N.
Further details regarding the statistical methods are provided
in Appendix 2, Methods.Results
Patient Demographics and Characteristics
Of the 65 patients screened, 48 were eligible and enrolled from
12 sites (6 in the US [n = 26] and 1 each in Australia [n = 2],
Canada [n = 11], Germany [n = 6], Spain [n = 1], Switzerland118[n= 1], and Taiwan [n= 1]). The first patient was born in 1970
and the last in 2011. Among the 48 patients, 13 (27%) were
diagnosed with hypophosphatasia before 1990, 14 (29%) be-
tween 1990 and 1999, and 21 (44%) during or after 2000. Thir-
teen (27%) were alive (median [min, max] age: 7.7 [2, 20]
years), and 35 (73%) had died (Kaplan–Meier median [95%
CI] age at death: 0.7 [0.4, 1.2] years) (Figure 1; available at
www.jpeds.com). Patients who had died comprised 100%
(13/13) of those diagnosed before 1990, 71.4% (10/14) of
those diagnosed between 1990 and 1999, and 57.1% (12/21)
of those diagnosed in 2000 or later, suggesting some
improvement in survival with better availability and/or
advances in supportive care. Their demographic and disease
characteristics are summarized in Table I. As required for
study inclusion, all presented with at least 1 of the specified
key characteristics of hypophosphatasia before 6 months of
age (median [min, max] age: 1 [0, 179] days). Median (min,
max) age of hypophosphatasia diagnosis was 0.2 (0, 3) years.
Consistent with the range of severity of their
hypophosphatasia, median (min, max) age of
hypophosphatasia diagnosis among the 13 patients who were
alive at the time of chart review was 0.4 (0, 3) years, and
among the 34 patients who were dead and had this
information recorded was 0.04 (0, 0.8) years. Among the
total patient group, 14 (29%) were reported to have prenatal
ultrasound scan manifestations of hypophosphatasia, 15
(31%) were not reported to have evidence of
hypophosphatasia on prenatal ultrasound scan, and 19
(40%) had no available ultrasound scan data. In the 29
patients whose charts had sufficient information (23/35 dead
and 6/13 alive), signs of hypophosphatasia reported on
prenatal ultrasound scan were similar between those who
would die and those who would live (12/23 vs 2/6,
respectively).
One patient was stillborn, and 13 patients died within the
first month of life; 9 on the first day, and 4 on days 5, 11, 27,
and 31. In total, 10 of these 14 patients received respiratory
support before death. Of the 14, 7 (50%) were diagnosed
before 1990 (and only 1 was diagnosed before 1980), 3
(21%) were diagnosed between 1990 and 2000, and 4
(29%) were diagnosed after 2000. The infant who was still-
born could not be assessed for the key inclusion characteris-
tics but was enrolled based on his profoundly low serum ALP
activity, radiographic findings, and respiratory compromise
that was attributed to pulmonary hypoplasia (cause of
death). Among the 35 patients who would die, the most prev-
alent complication, as anticipated, was respiratory compro-
mise (33/35).
At hypophosphatasia diagnosis, serum ALP was available
for 85% (41/48) of patients (mean  SD [min, max]:
18.1  15.4 [0, 55.0] U/L). ALP reference ranges were pro-
vided for 26 of these patients; all 26 patient values were below
the mean lower limit of normal of the reference ranges of the
various laboratories (88.2 U/L). Among the 13 patients who
were alive at the time of chart review, 12 (92%) had recorded
serum ALP activity (mean  SD [min, max]: 34.0  14.5
[2.0, 55.0] U/L). Among the 35 patients who were dead atWhyte et al
Table I. Patient demographics and diagnostic history
Characteristics Overall Alive Dead
Demographics
Gestational age at birth n = 36 n = 12 n = 24
Median (min, max), wk 39 (30, 41) 38.5 (35, 41) 39.0 (30, 41)
Age at data collection for living patients n = 13 n = 13
Median (min, max), y 7.7 (2, 20) 7.7 (2, 20) —
Sex, n (%) n = 48 n = 13 n = 35
Male 26 (54) 6 (46) 20 (57)
Female 22 (46) 7 (54) 15 (43)
Region of birth, n (%) n = 48 n = 13 n = 35
North America 33 (69) 5 (39) 28 (80)
Europe 8 (17) 7 (54) 1 (3)
Australia 2 (4) 0 2 (6)
Middle East 1 (2) 1 (8) 0
Asia 1 (2) 0 1 (3)
Unknown* 3 (6) 0 3 (9)
Race, n (%) n = 48 n = 13 n = 35
White 40 (83) 11 (85) 29 (83)
Black or African American 3 (6) 0 3 (9)
Asian 2 (4) 1 (8) 1 (3)
American Indian or Alaska Native 1 (2) 1 (8) 0
Unknown 2 (4) 0 2 (6)
Ethnicity, n (%) n = 48 n = 13 n = 35
Not Hispanic or Latino 41 (85) 12 (92) 29 (83)
Hispanic or Latino 1 (2) 0 1 (3)
Unknown 6 (13) 1 (8) 5 (14)
Diagnostic history
Signs of in utero skeletal disease on ultrasound scan, n (%) n = 48 n = 13 n = 35
Yes 14 (29) 2 (15) 12 (34)
No 15 (31) 4 (31) 11 (31)
Unknown 19 (40) 7 (54) 12 (34)
Age at onset of signs/symptoms, mo n = 47 n = 13 n = 34
Mean (SD) 1.1 (1.7) 2.3 (2.1) 0.7 (1.2)
Median (min, max) 0.03 (0, 5.9) 2.4 (0, 5.9) 0.03 (0, 5.2)
Age at hypophosphatasia diagnosis, mo n = 47 n = 13 n = 34
Mean (SD) 5.2 (9.3) 13.7 (14.3) 1.9 (2.5)
Median (min, max) 2.0 (0, 40.9) 4.4 (0.2, 40.9) 0.5 (0, 10.1)
Criteria that formed the basis for diagnosis of hypophosphatasia,† n (%) n = 48 n = 13 n = 35
Clinical laboratory results
Serum ALP 41 (85) 11 (85) 30 (86)
Plasma PLP 6 (13) 7 (54) 6 (17)
Urinary PEA 12 (25) 7 (54) 5 (14)
Other: serum calcium 3 (6) 0 3 (9)
Radiographic findings 38 (79) 11 (85) 27 (77)
Signs and symptoms 25 (52) 11 (85) 14 (40)
ALPL gene mutation 17 (35) 9 (69) 8 (23)
Laboratory test results
Serum ALP activity, U/L n = 41 n = 12 n = 29
Mean (SD) 18.1 (15.4) 34.0 (14.5) 11.6 (10.3)
Median (min, max) 15.0 (0, 55.0) 34.0 (2.0, 55.0) 10.0 (0, 42.0)
Plasma PLP, ng/mL n = 6 n = 5 n = 1
Mean (SD) 623 (1154) 154 (93) 2972 (NA)
Median (min, max) 150 (43, 2972) 150 (43, 300) 2972 (2972, 2972)
Serum calcium, mmol/L n = 32 n = 11 n = 21
Mean (SD) 2.8 (0.4) 2.7 (0.3) 2.8 (0.4)
Median (min, max) 2.6 (2.3, 4.0) 2.6 (2.4, 3.5) 2.7 (2.3, 4.0)
NA, not available.
*Recorded as unknown.
†Diagnosis was based on a combination of laboratory findings, a combination of laboratory and radiographic findings, or genetic analysis (see inclusion criteria). ALPL gene mutation analysis was not
required for diagnosis. Reference ranges for each laboratory varied.
June 2019 ORIGINAL ARTICLESthe time of chart review, 29 (83%) had substantially lower re-
corded serum ALP activity (mean  SD [min, max]:
11.6 10.3 [0, 42.0] U/L), suggesting correlation with hypo-
phosphatasia severity. Plasma PLP level was elevated above
the mean ULN of the various laboratories (31.3 ng/mL) in
all of the few patients with such data (n = 6), with a
mean  SD (min, max) of 623  1154 (43, 2972) ng/mL.
Mean  SD (min, max) serum 25-hydroxyvitamin D
Natural History of Perinatal and Infantile Hypophosphatasia: A Re(84.8  13.5 [73.9, 99.8] nmol/L; n = 3) was within the
normal reference ranges of the various laboratories (mean
lower limit of normal: 53.2 nmol/L; mean ULN:
172.0 nmol/L). Hypercalcemia had been documented in 14
of 21 patients, and hyperphosphatemia had been reported
in 10 of 21 patients with available data. Mean  SD (min,
max) serum calcium concentration (2.8  0.4 [2.3, 4.0]
mmol/L [11.2 mg/dL]; n = 32) was above the mean ULNtrospective Study 119
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mean 1.1-fold elevation. Mean  SD (min, max) serum
phosphate concentration (2.0  0.4 [1.1, 3.1] mmol/L
[6.19 mg/dL]; n = 29) matched the mean ULN of the various
laboratories (2.0 mmol/L; 6.19 mg/dL). Mean  SD (min,
max) serum creatinine concentration (136.6  325.5 [0.1,
1246.4] mmol/L [1.55 mg/dL]; n = 23) was elevated at the
time of hypophosphatasia diagnosis compared with the
mean ULN of the various laboratories (68.3 mmol/L;
0.77 mg/dL) because of 2 especially high values. The values
were proportionately distributed as “low” (5/16), “normal”
(7/16), and “high” (4/16) within the reference ranges.
ALPL mutation analysis results obtained using early
sequencing techniques at a variety of commercial and
research laboratories between March 1995 and November
2011 were reported for 21 patients; mutations were detected
in 19. Most patients were compound heterozygotes (12/19),
and the remainder carried homozygous mutations (5/19)
or seemed to carry heterozygous mutations (2/19). For the
2 patients without an identified ALPL mutation, copy num-
ber variation or reverse transcriptase polymerase chain reac-
tion had not been performed. Because these 2 patients had
laboratory and radiographic findings characteristic of severe
hypophosphatasia, they were included in the study.
At the time of hypophosphatasia diagnosis, radiographic
findings had been reported in the medical record for 77%
of patients (37/48). Multiple skeletal abnormalities were
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120as well as the study inclusion criterion of rachitic chest defor-
mity (32/37) (Table II; available at www.jpeds.com).
Radiographic absence of some or all bones was described in
7 of 30 patients. Of these 7 patients, 5 had signs and
symptoms of hypophosphatasia at birth or reported within
1 day of birth.
Respiratory Support Requirements and
Invasive Ventilation-Free Survival
Forty-five (94%) of the 48 patients had documented respira-
tory status. Of the 45, 29 had received either “noninvasive” or
“invasive” respiratory support. At the time we collected their
data, 26 of the 29 patients had died (Figure 2). Respiratory
support was necessary within the first 6 days of life for
most of these patients (17/29). Invasive ventilation was
necessary for 19 of the 29 patients, supplemental oxygen
was necessary in 9, and continuous positive airway pressure
was necessary in 1. Death occurred for 18 of the 19 who
received invasive ventilation (Figure 2).
Among the 48 patients, the median IVFST was 7.8 months
(95% CI 2.6-9.9; Figure 3). The Kaplan–Meier estimate of
probability of being alive and not invasively ventilated
during the first year of life was 63% at 3 months, 54% at
6 months, and 31% at 12 months. Only 25% of patients
were alive at 5 years of age (Figure 3). Rates of respiratory
support–free survival (data not shown) were comparable
with rates of IVFST, as respiratory support was invasive in
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Figure 3. Kaplan–Meier plot of time from birth during which patients were not mechanically ventilated by intubation or tra-
cheostomy; 36 patients had an event of invasive ventilation or death, and 12 were censored. Inset: cumulative probability of
invasive ventilation-free survival.
June 2019 ORIGINAL ARTICLESindividual patient ventilation status is in Table III (available
at www.jpeds.com).
Common Signs, Symptoms, and Complications
Associated with Hypophosphatasia
Table IV summarizes the incidence/prevalence of the
most common complications of perinatal and infantile
hypophosphatasia noted in this study population, as well
as their association with mortality. The eligibility criteria
conditioned the high prevalence of chest deformity (39/43),
respiratory distress (30/39), and respiratory failure (26/36).
Respiratory distress and failure and vitamin B6–dependentTable IV. Hypophosphatasia presentation stratified by age i
Signs, symptoms, or complications
Observed incidence, % (n/N)*
Overall







Respiratory failure 72 (26/36) 47 (18/38) 42 (8/19) 0 (0
Respiratory distress 77 (30/39) 64 (25/39) 50 (10/20) 18 (2
Decreased oxygen saturation 67 (22/33) 53 (16/30) 53 (10/19) 0 (0
Tachypnea 63 (20/32) 53 (17/32) 47 (8/17) 18 (2
Vitamin B6–dependent seizures 26 (10/38){ 17 (6/36) 14 (3/21) 0 (0
Elevated serum or urine calcium 72 (28/39) 68 (26/38) 74 (14/19) 18 (2
Pneumonia 42 (15/36) 18 (6/34) 50 (10/20) 18 (2
Nephrocalcinosis 52 (16/31) 36 (11/31) 63 (10/16) 40 (4
Chest deformity 91 (39/43) 80 (28/35) 96 (22/23) 83 (1
Respiratory tract infection 64 (21/33) 42 (13/31) 79 (15/19) 46 (5
Craniosynostosis 61 (19/31) 50 (15/30) 74 (14/19) 64 (7
Failure to thrive 76 (28/37) 67 (24/36) 91 (19/21) 64 (7
Early tooth loss 44 (10/23) 0 (0/24) 71 (10/14) 78 (7
*Calculated as the number of patients with disease history (n) divided by the number of patients with
†Number of patients who were dead (n) divided by the total number of patients (both alive and dea
‡Number of patients who were dead (n) divided by the total number of patients (both alive and dea
§Relative risk significantly different from 1 (P < .05).
{Seven patients had documented vitamin B6–dependent seizures; an additional 3 patients had a his
was not available for these 3 patients).
Natural History of Perinatal and Infantile Hypophosphatasia: A Reseizures were associated significantly (P < .05) with the risk
of early death independent of other confounding risk
factors (Table IV). In addition, 24 of 27 patients with
appropriate data for age reportedly had developmental
delays, including gross motor skills (23/24), walking (10/
24), and fine motor skills (2/24). Cognitive delays were
documented for 3 of 19 of patients with available data.
Medication Histories and Hospitalizations
Treatment histories were positive for medications or other
therapies for hypophosphatasia signs and symptoms for
most patients (65% [31/48]).Medications included adrenergicnterval and association with death
Relative risk (95% CI) of
death in patients with vs without
the manifestation







/11) 10 (1.56-64.20)§ 100 (26/26) 10 (1/10)
/11) 2.6 (1.02-6.62)§ 87 (26/30) 33 (3/9)
/10) 1.8 (0.92-3.54) 82 (18/22) 45 (5/11)
/11) 1.7 (0.94-3.08) 85 (17/20) 50 (6/12)
/11) 1.6 (1.18-2.06)§ 100 (10/10) 64 (18/28)
/11) 1.2 (0.72-1.94) 75 (21/28) 64 (7/11)
/11) 1.1 (0.72-1.69) 73 (11/15) 67 (14/21)
/10) 1.0 (0.63-1.68) 69 (11/16) 67 (10/15)
0/12) 0.7 (0.54-0.84)§ 67 (26/39) 100 (4/4)
/11) 0.7 (0.49-1.13) 62 (13/21) 83 (10/12)
/11) 0.7 (0.41-1.20) 53 (10/19) 75 (9/12)
/11) 0.6 (0.45-0.82)§ 61 (17/28) 100 (9/9)
/9) 0 (–, –) 0 (0/10) 92 (12/13)
available data (N) 100. Patients for whom status was unknown or missing were not included.
d) with the complication (N).
d) without the complication (N).
tory of vitamin B6–dependent seizures based upon hospitalization and medication records (age
trospective Study 121
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corticosteroids, loop diuretics, anticonvulsants, and vitamin
B6. Two patients, both alive at the time of chart review, had
been our research subjects and received a bone marrow trans-
plantation during infancy,15,16 followed soon after by stromal
cell transplantation in one.15 Thirty-nine (81%) of the 48 pa-
tients had hospitalizations during their first 5 years of life, 22
from respiratory compromise complications and 7 from
seizure-related complications. Multiple hospitalizations,
some prolonged, had occurred for most living and dead pa-
tients. Approximately one-half of the patients who had died
(18/35) and one-third of the living patients (4/13) had hospi-
talization(s) for respiratory compromise. (Additional infor-
mation concerning the hospitalizations is shown in Table V
[available at www.jpeds.com].)Discussion
This chart review collected natural history data from pa-
tients with perinatal or infantile hypophosphatasia (ie,
hypophosphatasia-related findings apparent at birth or
manifesting in the first 6 months of life, respectively).
Data were collected up to 5 years of life. In earlier reports,
we described the natural history of hypophosphatasia
selectively in 15 Manitoban patients with perinatal hypo-
phosphatasia10 and documented the natural history of hy-
pophosphatasia spanning an average of 6.5 years in
children with odonto-, mild childhood, severe childhood,
and infantile hypophosphatasia.17 Our current study is a
multinational systematic assessment of the natural history
of specifically perinatal and infantile hypophosphatasia
caused by a wide variety of ALPL mutations. Patients
selected for this study were required to have a history of
rachitic chest deformity, respiratory compromise, or
vitamin B6–dependent seizures to represent the extreme
end of the hypophosphatasia disease spectrum and, there-
fore, to reflect the perinatal and infantile hypophosphata-
sia patient population involved in a clinical study of
asfotase alfa treatment.12,14 Patients with benign prenatal
hypophosphatasia9 were excluded, as shown by the severe
clinical course of the study subjects.
Our data from 48 patients manifesting complications of
hypophosphatasia before 6 months of life, and frequently
within the first month of life, showed that skeletal disease
in utero was suspected based on prenatal ultrasound scan
in only one-third. Perhaps this has changed with more
advanced and prevalent use of this technology, or it indicates
that postnatal presentation of the disorder is common.
Although the median age at diagnosis of hypophosphatasia
was 0.2 years, diagnosis also was made as late as 3 years of
age. Patients who had died at the time of chart review had
been diagnosed earlier than those who were alive at chart re-
view and had numerically lower mean serum ALP activity.
However, these results should be interpreted with caution,
as statistical comparisons of ALP activity between alive and
dead patients seemed problematic because of differences in122sample collection (eg, sites, time periods, assays). Delays in
diagnosis for some patients that occurred despite the pres-
ence of the most severe characteristics of hypophosphatasia
underscore the need for better appreciation of the signs,
symptoms, and biochemical and radiographic hallmarks of
hypophosphatasia, especially now that an effective treatment
is available for patients with hypophosphatasia, including for
severely affected newborns and infants.14,18
The 13 surviving patients in our study nevertheless suf-
fered significant morbidity during their first 5 years of life.
Those with available data had failure to thrive and chest
deformity, but reportedly none had vitamin B6–dependent
seizures, which in hypophosphatasia is considered a sign of
impending death.6,19 At least one-half of the 13 surviving
patients went on to manifest early deciduous tooth loss, res-
piratory tract infection, respiratory compromise, craniosy-
nostosis, hypercalcemia, and/or nephrocalcinosis.
Respiratory complications that troubled these survivors
included decreased oxygen saturation, distress, pneumonia,
and tachypnea, although none progressed to chronic respi-
ratory failure during the time frame of data collection and
only 1 transiently was given ventilation. All patients with
vitamin B6–dependent seizures and respiratory failure
died, as did most requiring any respiratory support (26/
32). Finally, within the time frame of this study, all but 1
surviving patient reportedly had developmental (motor)
delays and 2 reportedly had cognitive delays. The motor de-
lays were readily attributed to their skeletal abnormalities
and muscle weakness.12,14,20
We focused in 201613 on the overall mortality rate of 73%
by 5 years of age in this current study population, with the
greatest relative risks for death noted among patients with
the inclusion criteria of respiratory failure, respiratory
distress, and vitamin B6–dependent seizures. Most of the
48 patients (58%) died within 12 months of birth, and me-
dian time to death was 8.9 months.13 Thus, our current anal-
ysis adds to what is known about mortality among these
patients. Although mortality was greatest among patients
diagnosed before 1990 (100%), the rate remained high for
those diagnosed between 1990 and 1999 (71%) and those
diagnosed in 2000 and later (57%), suggesting that mortality
rates for patients with perinatal and infantile hypophospha-
tasia with the aforementioned inclusion criteria remain
high even with modern neonatal and pediatric intensive
care units. The proportion of patients surviving without
invasive ventilation decreased during the first year, from
63% at 3 months to 31% at 12 months. The median time
from birth to invasive ventilation or death was 7.8 months.
Thus, these observations confirm published reports of high
mortality in general among patients with perinatal and infan-
tile hypophosphatasia receiving supportive care.1,2
As first published in 2012, asfotase alfa treatment in the
similar population of patients improved survival,12 with
84% (31/37) of patients alive at 5 years of age13 vs 27%
(13/48) in the current study. This emphasizes the importance
of prompt diagnosis of perinatal and infantile hypophospha-
tasia so that supportive measures and effective treatment canWhyte et al
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perinatal or infantile hypophosphatasia, and therefore either
form of hypophosphatasia requires close monitoring. Chest
deformities and failure to thrive are common acquired fea-
tures of infantile hypophosphatasia12 but, in the current
study, were associated with a somewhat-lower risk of death
compared with respiratory failure or compromise or, as pub-
lished in 2007, with vitamin B6–dependent seizures.6 These
latter 2 characteristics of severe hypophosphatasia were asso-
ciated with greater mortality in this study, likely because pul-
monary compromise is understandably life-threatening and
vitamin B6–dependent seizures likely signal the most pro-
found deficiency of TNSALP activity. In fact, a similar
finding was recently reported among Japanese patients with
perinatal hypophosphatasia, where failure to thrive did not
correlate with a poorer prognosis.20 However, a rachitic chest
and failure to thrive are typically diagnosed in infants who
have survived at least several weeks, permitting these compli-
cations to manifest.10,12,21 Possibly, chest deformity or failure
to thrive affected some patients in our study but went unre-
ported. The relatively small number of patients in the multi-
national study reported herein may have been insufficient
to identify further signs and symptoms that influenced
mortality.
Our study was retrospective and often limited by the avail-
able data in case files. Data concerning motor and cognitive
delays were collected from chart review and had not been as-
sessed with standardized tools. Furthermore, the eligibility
criteria were such that patients would be excluded if their
signs and symptoms represented relatively mild infantile hy-
pophosphatasia, which therefore likely increased the overall
relative risks. In addition, the study included data reflecting
a timeframe of perhaps 41 years (the first patient was born
in 1970, and the last in 2011) and enrolled 48 patients. This
small number of study subjects representing many years of
follow-up may not have provided sufficient statistical power
to identify correlations between outcomes and additional
insidious features of hypophosphatasia. Furthermore, the
broad time span for data acquisition did not fully reflect
recent advances in pediatric intensive care, including respira-
tory support and ventilation. Lastly, the associations between
risk factors and mortality were analyzed individually without
considering mutual correlation and potentially confounding
aspects among risk factors. Importantly, the most common
complications of hypophosphatasia are subject to survivor-
ship bias, such as tooth loss and, therefore, might take longer
to develop.
In conclusion, this retrospective natural history study
confirmed a high rate of morbidity and mortality among
patients with perinatal and infantile hypophosphatasia
within the first 5 years of life. Respiratory failure and vitamin
B6-dependent seizures are comorbidities highly predictive of
early death. Our observations are of particular significance
because with the availability of an effective enzyme
replacement therapy (asfotase alfa)14,18 future natural history
studies in this population of young children are unlikely. nNatural History of Perinatal and Infantile Hypophosphatasia: A ReWe acknowledge the International Skeletal Dysplasia Registry (http://
ortho.ucla.edu/isdr), from which a number of cases were identified.
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Metab 2013;11:60-70.50 Years Ago in THE JOURNAL OF PEDIATRICSFunduscopic Photography and Fluorescein Angioretinography in
Evaluation of Children with Neurologic Handicaps
Baird HW, Pileggi AJ, Harley RD. J Pediatr 1969;6:937-45.
Baird et al obtained funduscopic photographs with fluorescein angioretinography in 80 of 300 neurologicallyhandicapped children referred for ophthalmoscopic examination. Macular degenerative disease was present in
20. The authors further described 6 cases with different diagnoses and concluded that fundoscopic photography is a use-
ful tool for retinal examination of handicapped children. In the following years, however; a restricted field of view, reflec-
tion artefacts, universal need for general anesthesia, and specific positioning, cost, and availability were recognized as
major limitations to regular and widespread use of fundus photography and fluorescein angiography in children.
Fifty years later, the world of retinal imaging has surpassed most barriers. With the use of wide field and ultra-
widefield (UWF) imaging systems, it is possible to obtain ora-to-ora view of the retina.1 UWF has allowed to expand
the field of view of imaging from 30 to 60 to up to 200 in a single image, capturing more of the periphery at retina.2
Most pediatric retinal diseases manifest in peripheral retina and UWF angiography has proved to be extremely useful
to diagnose the proliferative and exudative changes. Although most cases still require general anesthesia or light
sedation, UWF fundus photography and angiography can be done as an outpatient procedure without the need for
anesthesia, using “flying-baby” technique to position the child primarily for retinopathy of prematurity screening.2
Confocal scanning laser ophthalmoscopy, allows for elimination of artefact reflections. Portable wide-angle cameras
are now available for fundus photography, which allow direct visualization and capture in pediatric patients unable to
position themselves.3 These, and the advent of smart phone fundus photography, have opened up new gateways for
telemedicine consulting and screening programs.3
Fundus imaging now plays an important role in retinopathy of prematurity, familial exudative vitreoretinopathy,
Coats disease, Incontentia pigmenti, X-linked retinoschisis, Stargardt disease, Best disease, toxoplasmosis chorioreti-
nitis, juvenile sarcoidosis, choroidal melanoma, juvenile idiopathic arthritis, pars planitis, and traumatic retinal
detachment.2 Recent imaging tools have not only allowed improved diagnosis, screening, documentation,
monitoring, and image-guided treatment of these diseases. They have also widened the scope of research.
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Screened (N=65) Screen failure (n=17 [26%])
• Lack of documented diagnosis of 
                                only (n=13)
• Onset of signs and symptoms of 
                               at age >6 mo
only (n=3)
• Both (n=1)
Alive at data 
abstraction (n=13 [27%])
Dead at data 
abstraction (n=35 [73%])
• Respiratory compromise and rachitic chest (n=18)
• Respiratory compromise, rachitic chest, and 
vitamin B6–dependent seizures (n=8)
• Respiratory compromise and vitamin 
B6-dependent seizures (n=2)
• Respiratory compromise only (n=5)
• Rachitic chest only (n=1)
• Stillborn, pulmonary hypoplasia (n=1)
• Respiratory compromise and rachitic chest (n=7)






(key eligibility criteria)  
Hypophosphatasia characteristics
(key eligibility criteria)  
Figure 1. Patient disposition flowchart.
Table II. Radiographic findings reported at
hypophosphatasia diagnosis
Radiographic findings %* (n/N)
Osteopenia 89 (33/37)
Rachitic chest/deformed ribs 86 (32/37)†
Metaphyseal fraying 68 (19/28)
Metaphyseal flaring 67 (20/30)
Metaphyseal radiolucencies (tongues) 63 (15/24)
Metaphyseal widening 55 (12/22)
Long bone bowing 48 (14/29)
Thin, gracile bones 44 (12/27)
Sclerosis 30 (6/20)
Bony spurs 26 (6/23)
Fracture (nonunion) 23 (7/30)
Absence of some/all bones 23 (7/30)
*Percent calculated as the number of patients with the finding (n) divided by the number of pa-
tients with available data (N) 100. Patients for whom status was “unknown” or missing were
not included.
†A total of 39 patients had chest deformity documented in disease history (Table IV in the main
text) and 32 patients had radiographic evidence of rachitic chest at the time of diagnosis.
THE JOURNAL OF PEDIATRICS  www.jpeds.com Volume 209
124.e2 Whyte et al
Table III. Respiratory support type* for each patient
BiPAP, bilevel positive airway pressure; CPAP, continuous positive airway pressure; IV, invasive ventilation.
Types of respiratory support are color-coded, with each type of support appearing in the same color.
*Respiratory support types from greatest to least: IV, CPAP, BiPAP, and/or supplemental oxygen.
†Age (years/months/days) at which respiratory support was initiated, if available, is indicated in parentheses.
‡Last respiratory support is the type of support that was needed up to age 5 years for patients who were alive or the final support applied before death.
§Age (years/months/days) at death, if available, is indicated in parentheses. If patient was alive, requirement for respiratory support at age 5 years, if needed, is indicated.
{Patient was stillborn.
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Table V. Hospitalizations for reasons consistent with a diagnosis of hypophosphatasia
Reasons
All patients (N = 48) Deceased patients (n = 35) Living patients (n = 13)
Hospitalizations, n Patients, n (%)* Patients, n (%)† Patients, n (%)†
Hospitalizations for any reason 133 39 (81) 27 (77) 12 (92)
All respiratory compromise 46 22 (46) 18 (51) 4 (31)
Respiratory failure 5 2 (4) 2 (6) 0 (0)
Respiratory distress 21 12 (25) 11 (31) 1 (8)
Other‡ 20 11 (23) 7 (20) 4 (31)
Craniosynostosis 16 9 (19) 4 (11) 5 (39)
Seizure related 8 7 (15) 6 (17) 1 (8)§
Renal related 3 2 (4) 1 (3) 1 (8)
Others{ 62 28 (58) 16 (46) 12 (92)
*Percentage is calculated as n divided by 48, the number of enrolled patients,  100.
†Percentage is calculated using the number of deceased or alive patients.
‡Includes pneumonia, asthma, tachypnea, dyspnea, tachydyspnea, asthma, ventilator use, labored respirations, ventilatory care.
§Reason was to eliminate possibility of seizures.
{Reasons included hypercalcemia, infections, vomiting, failure to thrive/developmental delays, hypophosphatasia evaluation/diagnostics, orthopedic treatment (surgery, casts, fractures), exper-
imental therapies (stem cell or bone marrow transplants, enzyme replacement using Paget’s bone disease plasma infusions), abdominal pain, rehabilitation, icterus neonatorum, choking, head
injury/concussion, nasal gastric tube placement, prematurity, cardiac failure, patent ductus arteriosus ligation. Patients may have had multiple hospitalizations. Patients and hospitalizations
may be counted in multiple “reasons” categories.
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